Clinical Trial Update: A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast [NA]

View source ↗

Summary

Terminated clinical trial evaluating an SPIO-based contrast agent for MR lymphangiography. Results were posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Prostate Cancer

Drugs mentioned

• SPIO-based MR lymphangiography contrast agent (superparamagnetic iron oxide nanoparticles)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Bladder Cancer, Genitourinary Cancer | NA | Status: TERMINATED | Results posted: 2010-01-27